[go: up one dir, main page]

MX2013015272A - Cristales micronizados. - Google Patents

Cristales micronizados.

Info

Publication number
MX2013015272A
MX2013015272A MX2013015272A MX2013015272A MX2013015272A MX 2013015272 A MX2013015272 A MX 2013015272A MX 2013015272 A MX2013015272 A MX 2013015272A MX 2013015272 A MX2013015272 A MX 2013015272A MX 2013015272 A MX2013015272 A MX 2013015272A
Authority
MX
Mexico
Prior art keywords
micronized crystals
atorvastatin hemicalcium
micronized
crystals
calcium
Prior art date
Application number
MX2013015272A
Other languages
English (en)
Inventor
Neeraj Tewari
Rajnish Kumar
Original Assignee
Dsm Sinochem Pharm Nl Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Sinochem Pharm Nl Bv filed Critical Dsm Sinochem Pharm Nl Bv
Publication of MX2013015272A publication Critical patent/MX2013015272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00—Other disintegrating devices or methods
    • B02C19/06—Jet mills
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a cristales micronizados de atorvastatina hemi-cálcica, a un método para la preparación de cristales micronizados de atorvastatina hemi-cálcica y a una forma de dosificación farmacéutica que comprende dichos cristales micronizados de atorvastatina hemi-cálcica.
MX2013015272A 2011-07-01 2012-06-28 Cristales micronizados. MX2013015272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11172440 2011-07-01
PCT/EP2012/062592 WO2013004591A1 (en) 2011-07-01 2012-06-28 Micronized crystals of atorvastatin hemicalcium

Publications (1)

Publication Number Publication Date
MX2013015272A true MX2013015272A (es) 2014-04-14

Family

ID=44685910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015272A MX2013015272A (es) 2011-07-01 2012-06-28 Cristales micronizados.

Country Status (6)

Country Link
US (1) US20140335179A1 (es)
EP (1) EP2726456A1 (es)
CN (1) CN103702982A (es)
IL (1) IL229821A0 (es)
MX (1) MX2013015272A (es)
WO (1) WO2013004591A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071787A1 (es) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105111123A (zh) * 2013-11-25 2015-12-02 李兴惠 阿托伐他汀钙及组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
CA2150372C (en) 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5686014A (en) 1994-04-07 1997-11-11 The Procter & Gamble Company Bleach compositions comprising manganese-containing bleach catalysts
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EA000474B1 (ru) 1995-07-17 1999-08-26 Варнер-Ламберт Компани Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TR199900191T2 (xx) 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
JP2001526256A (ja) 1997-12-19 2001-12-18 ワーナー−ランバート・エクスポート・リミテッド １，３−ジオールの合成方法
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
KR100609371B1 (ko) 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
US20110064816A1 (en) 2008-05-13 2011-03-17 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071787A1 (es) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Also Published As

Publication number Publication date
IL229821A0 (en) 2014-03-06
WO2013004591A1 (en) 2013-01-10
CN103702982A (zh) 2014-04-02
EP2726456A1 (en) 2014-05-07
US20140335179A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MD20150091A2 (ro) Compuşi antivirali
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
EA201300388A1 (ru) Соединения замещенного бензамида
MY163083A (en) Solid forms of a pharmaceutically active substance
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2015005891A (es) Formas polimórficas de suvorexant.
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
MX2014004196A (es) Citramida de rasagilina.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX364400B (es) Compuestos de tetraciclina.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IN2014DN09451A (es)
IN2014DN03010A (es)
PH12013500210A1 (en) Highly crystalline valsartan
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
MX2013015272A (es) Cristales micronizados.
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять

Legal Events

Date Code Title Description
FA Abandonment or withdrawal